ClinicalTrials.gg
CompletedNCT03536585Updated Jun 2, 2023

Multi-polar RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity

An interventional study of Vulvovaginal treatment and Baseline in Vulvovaginal Atrophy, Menopause and Menopause Surgical, sponsored by Venus Concept. Completed at 3 sites in Canada. Open to female participants aged 30 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-02.

Sponsored by Venus Concept · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
30 Years to 80 Years
Sex
Female
01

Study summary

The study evaluates the use of multi-polar radiofrequency (RF) and pulsed electro-magnetic fields (PEMF) energies for the treatment of vaginal looseness and for the treatment of the mons pubis and labia for skin tightening. All subjects will receive a total of three internal and three external treatments at four week intervals. Subjects will be followed up at one and four months after treatment is complete.

Read the detailed description

Traditional non-surgical treatments to treat vaginal looseness include Kegel exercises or pelvic floor therapy with electrical stimulation of the vaginal muscles to promote muscle strength but may not be all that effective. Surgery is also used to tighten the vaginal canal and reduce the size of the mons pubis and the outer labial lips but can be associated with surgical complications. Development of new technologies to address these concerns is warranted.

Mutil-polar radiofrequency (RF) therapy to treat stress incontinence (attributed to looseness of the muscles that control the ability to hold urine) and looseness of the facial and neck skin has been used with success and minimal risk. The addition of pulsed electromagnetic field (PEMF) energy to multi-polar RF therapy has also been shown to improve the results of the RF therapy.

RF therapy has already been reported to be successful in vaginal tightening. This study will investigate whether adding PEMF to RF therapy is safe and efficacious for the treatment of vaginal loosenss. In addition, this study will also investigate whether RF and PEMF energy treatment will improve the looseness of the mons pubis and labia.

02

Conditions studied

  • Vulvovaginal Atrophy
  • Menopause
  • Menopause Surgical
03

In context

Lead sponsor

Venus Concept is the lead sponsor of 34 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 12 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female subjects, ≥30 years of age who are , or women who have undergone surgically induced menopause and are not able to bear children.
  2. Requesting treatment for vaginal laxity with a score of ˂4 on the VLQ and are requesting treatment of the mons pubis and labia for skin laxity.
  3. Sexual activity (vaginal intercourse minimum twice per month) in a monogamous relationship.
  4. Negative Papanicolaou (Pap) Smear Cytology Test within 3 months prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
  2. Having a permanent implant in the treated area.
  3. Prior use of collagen, fat injections and/or other methods of skin augmentation (enhancement with injected or implanted material) in the treated area within 4-6 weeks of the initial treatment or during the course of the study.
  4. Use of retinoids such as oral Isotretinoin (Accutane®) within 6 months of initial treatment or during the course of the study.
  5. Any other surgery in treated area within 12 months of initial treatment or during the course of the study.
  6. Open laceration, abrasion or bleeding of any sort on the area to be treated.
  7. Active sexual transmitted disease (STD) (e.g. genital Herpes Simplex, condylomata) or vaginosis.
  8. Chronic vulvar pain or vulvar dystrophy.
  9. History of /immune deficiency disorders (including infection or AIDS) or use of immunosuppressive medications, including , 6 months prior to and during the course of the study.
  10. Having any form of active cancer at the time of enrollment and during the course of the study.
  11. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the treatment, or healing process.
  12. Having any stage 3-4 cystocele, rectocele, enterocele paravaginal defect or major pelvic organ prolapse beyond the hymenal ring.
  13. Skin piercing in the treatment area.
  14. Tattoos in the treatment area.
  15. Prior procedure in the treated area with laser or other device within 12 months of the initial treatment or during the course of treatment.
  16. History of keloid formation or poor wound healing in a previously-injured skin area.

21. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).

21. Use of an intrauterine device during the course of treatment.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Vulvovaginal treatment

    Internal vaginal treatment monthly for 3 treatments; External mons pubis treatment monthly for 3 treatments; External labia treatment monthly for 3 treatments.

    Device: Vulvovaginal treatment · Device: Baseline

  • No intervention
    Baseline

    Subject's baseline photograph to act as their own control for the one-month and four-month post-treatment photograph of the mons pubis and labia.

Interventions

  • DeviceVulvovaginal treatment

    * Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes. * Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes. * Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes.

  • DeviceBaseline

    Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.

06

What researchers measure

Primary outcomes

  1. Vaginal Laxity

    Self reported improvement in vaginal laxity defined as a score \> 4 on Vaginal Laxity Questionnaire (VLQ) where 1 = very loose, 2 = moderately loose, 3 = slightly loose, 4 = neither tight nor loose, 5 = slightly tight, 6 = moderately tight and 7 = very tight.

    Time frame: Six months

07

Study locations

3 sites
  • Southern Health Centre
    White Rock, British Columbia V4B 5C9, Canada
  • Dr. George Arnold
    Markham, Ontario L6B 0T1, Canada
  • Pearl MD Rejuvenation
    Toronto, Ontario M4T 2A2, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Mar 2022, 46 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
May 24, 2018
StartActual
May 3, 2018
Primary completionActual
Mar 31, 2022
CompletionActual
Dec 31, 2022
Last update
Jun 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03536585
Lead sponsor
Venus Concept
Responsible party
Sponsor
First posted
May 24, 2018
Start date
May 3, 2018
Primary completion
Mar 31, 2022
Completion
Dec 31, 2022
Last update
Jun 2, 2023

Study contacts

Paul Cardarelli
study director · Venus Concept

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion